文献速递胸部肿瘤放疗

局部晚期非小细胞肺癌接受根治性放化疗后度伐利尤单抗巩固治疗患者肺炎的预测因素

Predictors of Pneumonitis in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation Followed by Consolidative Durvalumab.
PubMed 文献 · Adv Radiat Oncol · 2022-11-28

单中心62例局部晚期不可切除非小细胞肺癌患者接受根治性放化疗后度伐利尤单抗巩固治疗,中位随访17个月。2级及以上肺炎发生率为32.3%,3级及以上为9.7%。肺V20≥30%、平均肺剂量>18 Gy及平均心脏剂量≥10 Gy与2级及以上肺炎发生率升高相关。

要点

  • 2级及以上肺炎发生率为32.3%,3级及以上为9.7%。
  • 肺V20≥30%患者1年2级及以上肺炎发生率为49.8%,V20<30%为17.8%(P=.015)。
  • 平均肺剂量>18 Gy患者1年2级及以上肺炎发生率为52.4%,≤18 Gy为25.8%(P=.01)。

核心结论

  • 本队列肺炎发生率高于预期,尤其见于肺V20≥30%、平均肺剂量>18 Gy和平均心脏剂量≥10 Gy的患者,提示可能需要更严格的放疗计划剂量约束。

研究设计与样本

  • 单中心回顾性识别2018年至2021年接受根治性放化疗后度伐利尤单抗巩固治疗的局部晚期不可切除非小细胞肺癌患者,共纳入62例,中位随访17个月。

主要发现

  • 全队列2级及以上肺炎发生率为32.3%,3级及以上肺炎发生率为9.7%。
  • 肺V20≥30%患者1年2级及以上肺炎发生率为49.8%,肺V20<30%患者为17.8%(P=.015)。
  • 平均肺剂量>18 Gy患者1年2级及以上肺炎发生率为52.4%,平均肺剂量≤18 Gy患者为25.8%(P=.01)。
  • 平均心脏剂量≥10 Gy与2级及以上肺炎发生率升高相关。
  • 全队列估计1年总生存率为86.8%,1年无进展生存率为64.1%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In patients with locally advanced, unresectable non-small cell lung cancer (NSCLC), the standard of care is concurrent chemoradiation (CRT) followed by consolidative immunotherapy with durvalumab. Pneumonitis is a known adverse event of both radiation therapy and immune checkpoint inhibitors such as durvalumab. We sought to characterize pneumonitis rates and dosimetric predictors of pneumonitis in a real-world population of patients with NSCLC treated with definitive CRT followed by consolidative durvalumab. METHODS AND MATERIALS: Patients with NSCLC from a single institution who were treated with definitive CRT followed by consolidative durvalumab were identified. Outcomes of interest included pneumonitis incidence, type of pneumonitis, progression-free survival, and overall survival. RESULTS: Sixty-two patients were included in our data set treated from 2018 to 2021 with a median follow-up of 17 months. The rate of grade 2+ pneumonitis in our cohort was 32.3%, and the rate of grade 3+ pneumonitis was 9.7%. Lung dosimetry parameters including V20 ≥30% and mean lung dose (MLD) >18 Gy were found to be correlated with increased rates of grade 2+ and grade 3+ pneumonitis. Patients with a lung V20 ≥30% had a grade 2+ pneumonitis rate at 1 year of 49.8% compared with 17.8% in patients with a lung V20 <30% (P = .015). Similarly, patients with an MLD >18 Gy had a grade 2+ pneumonitis rate at 1 year of 52.4% compared with 25.8% in patients with an MLD ≤18 Gy (P = .01). Moreover, heart dosimetry parameters including mean heart dose ≥10 Gy were found to be correlated with increased rates of grade 2+ pneumonitis. The estimated 1-year overall survival and progression-free survival of our cohort were 86.8% and 64.1%, respectively. CONCLUSIONS: The modern management of locally advanced, unresectable NSCLC involves definitive chemoradiation followed by consolidative durvalumab. Pneumonitis rates were higher than expected in this cohort, particularly for patients with a lung V20 ≥30%, MLD >18 Gy, and mean heart dose ≥10 Gy, suggesting that more stringent radiation planning dose constraints may be needed.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Diamond BH, Belani N, Masel R, et al. Predictors of Pneumonitis in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation Followed by Consolidative Durvalumab. Adv Radiat Oncol. 2022. PMID: 36845618. doi:10.1016/j.adro.2022.101130

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。